Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.2
8.47
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Shanghai RAAS Blood Products Co Ltd stock under the Base Case scenario is 5.67 CNY. Compared to the current market price of 7.46 CNY, Shanghai RAAS Blood Products Co Ltd is Overvalued by 24%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Shanghai RAAS Blood Products Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Shanghai RAAS Blood Products Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Shanghai RAAS Blood Products Co Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Shanghai RAAS Blood Products Co., Ltd. is a key player in China's biopharmaceutical landscape, specializing in the production and supply of human blood products and diagnostic reagents. Founded in 1992, the company has grown to become one of the largest blood product manufacturers in the country, serving the increasing demand for high-quality and safe blood-derived therapies. The company’s extensive portfolio includes a range of products such as human albumin, immunoglobulins, and coagulants, which are essential for treating various medical conditions, from trauma care to chronic diseases. With a strong commitment to innovation and quality, RAAS has established robust research and developmen...
Shanghai RAAS Blood Products Co., Ltd. is a key player in China's biopharmaceutical landscape, specializing in the production and supply of human blood products and diagnostic reagents. Founded in 1992, the company has grown to become one of the largest blood product manufacturers in the country, serving the increasing demand for high-quality and safe blood-derived therapies. The company’s extensive portfolio includes a range of products such as human albumin, immunoglobulins, and coagulants, which are essential for treating various medical conditions, from trauma care to chronic diseases. With a strong commitment to innovation and quality, RAAS has established robust research and development capabilities, ensuring that it stays at the forefront of advancements in blood product technologies.
For investors, Shanghai RAAS represents a compelling opportunity in the rapidly expanding Chinese healthcare market. The company operates in a highly regulated environment, giving it a competitive edge through rigorous quality control and adherence to international standards. Furthermore, as China’s aging population grows and healthcare spending increases, the demand for reliable blood products is expected to rise significantly. RAAS has strategically positioned itself to capture this market growth, supported by a diversified customer base that includes hospitals and medical institutions. With its commitment to sustainability, innovation, and shareholder value, investing in Shanghai RAAS not only aligns with a growing industry but also offers the potential for solid returns as the company continues to expand its footprint in both domestic and international markets.
Shanghai RAAS Blood Products Co., Ltd. is a prominent player in the blood products industry in China. Its core business segments typically include the following:
-
Plasma-Derived Products: This segment involves the production and sale of various products derived from human plasma, including immunoglobulins, clotting factors, and albumin. These products are critical for treating a range of medical conditions, particularly those related to immune deficiencies and bleeding disorders.
-
Blood Collection and Processing: RAAS manages the collection and processing of human blood, contributing to its supply chain and ensuring the quality of the raw materials necessary for its products. This segment is crucial for maintaining an adequate and safe supply of plasma.
-
Research and Development (R&D): Investment in R&D is a fundamental aspect of RAAS's operations, focusing on innovative plasma products and improving extraction techniques and treatment methods. This segment supports the company’s growth and market competitiveness.
-
International Business: RAAS has been expanding its reach beyond China, seeking opportunities in international markets. This segment involves exporting products and potentially collaborating with foreign firms or regulatory bodies.
-
Health Services: The company may also provide healthcare services related to transfusion medicine, including blood banking and other related services.
These segments collectively underscore RAAS's commitment to healthcare and its role in addressing critical medical needs through high-quality blood products and services.
Shanghai RAAS Blood Products Co., Ltd. is a prominent player in the blood products industry, particularly in China. Several unique competitive advantages can help it stand out from its rivals:
-
Strong Market Position: As one of the leading blood product manufacturers in China, Shanghai RAAS has a significant market share, which offers economies of scale in production and a well-established distribution network.
-
Regulatory Expertise: The company has navigated the complex regulatory landscape in China effectively, allowing it to gain necessary approvals for its products more efficiently than some competitors.
-
Advanced Technology: Shanghai RAAS invests in advanced manufacturing processes and technologies, improving the quality and safety of its blood products while enhancing operational efficiency.
-
Comprehensive Product Portfolio: The company offers a wide range of blood products, including clotting factors and immunoglobulins, which can cater to diverse patient needs and create cross-selling opportunities.
-
Strong Research and Development: Continuous investment in R&D enables Shanghai RAAS to innovate and improve existing products while developing new ones, enhancing its competitive edge in the market.
-
Strategic Partnerships: Forming alliances with healthcare institutions and other pharmaceutical companies helps Shanghai RAAS leverage additional resources, distribution channels, and expertise.
-
Brand Reputation: Over the years, Shanghai RAAS has built a solid reputation for quality and reliability, which is crucial in the healthcare and pharmaceuticals industry.
-
Geographic Advantages: Being located in Shanghai, the company has access to one of the most developed healthcare ecosystems in China, including logistics, talent, and partnerships with research institutions.
-
Focus on Safety Standards: With increasing global focus on product safety in the health sector, Shanghai RAAS emphasizes compliance with high safety standards, which can be a strong selling point to customers and regulators alike.
-
Growing Demand for Blood Products: The increasing aging population and rising prevalence of blood-related diseases in China create a growing market for blood products, positioning Shanghai RAAS well for future growth.
These competitive advantages can help Shanghai RAAS maintain its leading position in the blood products market and effectively respond to the challenges posed by rivals.
Shanghai RAAS Blood Products Co Ltd, like any other company in the biopharmaceutical and biotechnology sectors, faces a variety of risks and challenges. Here are some key considerations for the near future:
-
Regulatory Risks: The healthcare sector is heavily regulated. Changes in regulations regarding blood products, quality standards, and approval processes could impact operations and market access.
-
Competition: The biopharmaceutical industry is competitive, with numerous players developing similar products. Market share may be impacted by new entrants, innovative technologies, or alternative therapies.
-
Supply Chain Disruptions: Dependence on a reliable supply chain for raw materials and components could be a risk, especially with global supply chain issues or geopolitical tensions that may affect sourcing.
-
Technological Advances: Rapid advances in biotechnology, including gene editing and synthetic biology, may lead to new products that could outdate existing offerings.
-
Market Demand Fluctuations: Changes in healthcare policies, demographics, or overall demand for blood products and derivatives can impact company revenue and growth forecasts.
-
Pricing Pressure: Increasing cost containment measures and pricing pressures from healthcare institutions and governmental policies can affect profitability.
-
Litigation Risks: The company may face lawsuits or legal challenges related to product liability, patent disputes, or compliance issues that could result in significant financial liabilities or reputational harm.
-
Public Perception and Trust: Any incidents related to safety, efficacy, or ethical considerations surrounding blood products can significantly impact public trust and demand.
-
Economic Conditions: Economic downturns may affect healthcare spending and, consequently, the demand for blood products.
-
R&D Challenges: Research and development efforts carry inherent risks, including failures in clinical trials, extended timelines, or unforeseen challenges that can delay or derail product launches.
-
International Market Risks: If the company expands internationally, it may face additional challenges related to market entry, currency fluctuations, and differing regulatory environments.
To mitigate these risks, it is essential for Shanghai RAAS Blood Products to focus on strong governance, robust R&D practices, strategic partnerships, and adaptive market strategies that align with industry changes and trends.
Revenue & Expenses Breakdown
Shanghai RAAS Blood Products Co Ltd
Balance Sheet Decomposition
Shanghai RAAS Blood Products Co Ltd
Current Assets | 8.2B |
Cash & Short-Term Investments | 3.4B |
Receivables | 1.1B |
Other Current Assets | 3.7B |
Non-Current Assets | 24.2B |
Long-Term Investments | 17B |
PP&E | 1.7B |
Intangibles | 5.3B |
Other Non-Current Assets | 132.9m |
Current Liabilities | 1.6B |
Accounts Payable | 1.1B |
Accrued Liabilities | 164.1m |
Short-Term Debt | 168.4k |
Other Current Liabilities | 343.5m |
Non-Current Liabilities | 45.4m |
Long-Term Debt | 1.5m |
Other Non-Current Liabilities | 43.9m |
Earnings Waterfall
Shanghai RAAS Blood Products Co Ltd
Revenue
|
8.3B
CNY
|
Cost of Revenue
|
-5B
CNY
|
Gross Profit
|
3.3B
CNY
|
Operating Expenses
|
-954.2m
CNY
|
Operating Income
|
2.3B
CNY
|
Other Expenses
|
-543.7m
CNY
|
Net Income
|
1.8B
CNY
|
Free Cash Flow Analysis
Shanghai RAAS Blood Products Co Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Shanghai RAAS Blood Products Co Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Shanghai RAAS Blood Products Co Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shanghai RAAS Blood Products Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Shanghai RAAS Blood Products Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shanghai RAAS Blood Products Co Ltd
According to Wall Street analysts, the average 1-year price target for Shanghai RAAS Blood Products Co Ltd is 6.94 CNY with a low forecast of 6.87 CNY and a high forecast of 7.14 CNY.
Dividends
Current shareholder yield for Shanghai RAAS Blood Products Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Shanghai RAAS Blood Products Co., Ltd. engages in the research and development, production and sales of blood products. The company is headquartered in Shanghai, Shanghai and currently employs 2,966 full-time employees. The company went IPO on 2008-06-23. The firm's main products include human albumin and human immunoglobulin for intravenous injection, human coagulation factors and others. The firm is also engaged in the distribution of Chinese medicine products and foods. The firm distributes its products within domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Shanghai RAAS Blood Products Co Ltd stock under the Base Case scenario is 5.67 CNY.
Compared to the current market price of 7.46 CNY, Shanghai RAAS Blood Products Co Ltd is Overvalued by 24%.